Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer?
Objective Integrative oncology (IO) has been shown to improve quality-of-life (QoL) and increase adherence to planned chemotherapy regimens. This study examined the impact of a patient-tailored IO program on adherence to chemotherapy among patients with advanced gynecological cancer. Methods This pr...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2022-05, Vol.30 (5), p.4345-4354 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4354 |
|---|---|
| container_issue | 5 |
| container_start_page | 4345 |
| container_title | Supportive care in cancer |
| container_volume | 30 |
| creator | Ben-Arye, Eran Nijk, Naama Lavie, Ofer Gressel, Orit MD, Elad Schiff Samuels, Noah |
| description | Objective
Integrative oncology (IO) has been shown to improve quality-of-life (QoL) and increase adherence to planned chemotherapy regimens. This study examined the impact of a patient-tailored IO program on adherence to chemotherapy among patients with advanced gynecological cancer.
Methods
This prospective non-randomized, pragmatic, preference study examined patients with stage III/IV gynecological cancers undergoing 6 weeks of weekly IO treatments. Adherence to the planned chemotherapy regimen was assessed using the relative dose intensity (RDI) calculation. Patients consistently attending IO treatments (consistent-IO group) were compared to those who were not (non-consistent IO group).
Results
RDI was calculated for 73 patients in the consistent-IO group (99 chemotherapy cycles) and 61 in the non-consistent-IO group (96 cycles with IO care, 126 cycles without). Both groups had similar baseline demographic characteristics, with endometrial cancer more prevalent in the consistent-IO group. RDI was significantly less reduced in the consistent-IO chemotherapy group (p = 0.005). During taxane-based regimens, RDI was better maintained in the consistent-IO group (0.93 vs. 0.87, p = 0.012), though not with platinum-based cycles. Linear regression model found a correlation between preserved RDI and consistent attendance at weekly IO treatments, and lower rates of chemotherapy-induced peripheral neuropathy and pain.
Conclusion
Patient-tailored IO programs for patients with advanced gynecological cancer may help preserve adherence to chemotherapy at 6 weeks, especially with taxane-based regimens. Further research needs to explore whether this correlation is chemotherapy agent–specific. |
| doi_str_mv | 10.1007/s00520-022-06865-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2624199275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A698110164</galeid><sourcerecordid>A698110164</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-618515b5dd2ff94ab1f41189ad8754f824022fdf5cc47d69e7a05fede05cf19f3</originalsourceid><addsrcrecordid>eNp9kUuLFDEUhYMoTjv6B1xIgRs3NebmVZWVDI0vGHCjKxchndzU1FCVtEn1QP97U9OjgyKSReCc71zu5RDyEugFUNq9LZRKRlvKWEtVr2TLHpENCM7bjnP9mGyoFtAKLuUZeVbKDaXQdZI9JWdcrpaADfm-tbEZ44JDtst4i02KLk1pOFbRZbQFG-uvMWN02Cypcdc4p6UKdr8i1by11fLNcIx4lxxd41Ypv3tOngQ7FXxx_5-Tbx_ef91-aq--fPy8vbxqnejV0iroJcid9J6FoIXdQRAAvba-76QIPRP1wuCDdE50XmnsLJUBPVLpAujAz8mb09x9Tj8OWBYzj8XhNNmI6VAMU0yA1qyTFX39F3qTDjnW7SolGIBUXDxQg53QjDGkJVu3DjWXSvcAFNRKXfyDqs_jPLoUMYxV_yPATgGXUykZg9nncbb5aICatVFzatTUe81do4bV0Kv7jQ-7Gf3vyK8KK8BPQKlWHDA_nPSfsT8BVbqqQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642115634</pqid></control><display><type>article</type><title>Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer?</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ben-Arye, Eran ; Nijk, Naama ; Lavie, Ofer ; Gressel, Orit ; MD, Elad Schiff ; Samuels, Noah</creator><creatorcontrib>Ben-Arye, Eran ; Nijk, Naama ; Lavie, Ofer ; Gressel, Orit ; MD, Elad Schiff ; Samuels, Noah</creatorcontrib><description>Objective
Integrative oncology (IO) has been shown to improve quality-of-life (QoL) and increase adherence to planned chemotherapy regimens. This study examined the impact of a patient-tailored IO program on adherence to chemotherapy among patients with advanced gynecological cancer.
Methods
This prospective non-randomized, pragmatic, preference study examined patients with stage III/IV gynecological cancers undergoing 6 weeks of weekly IO treatments. Adherence to the planned chemotherapy regimen was assessed using the relative dose intensity (RDI) calculation. Patients consistently attending IO treatments (consistent-IO group) were compared to those who were not (non-consistent IO group).
Results
RDI was calculated for 73 patients in the consistent-IO group (99 chemotherapy cycles) and 61 in the non-consistent-IO group (96 cycles with IO care, 126 cycles without). Both groups had similar baseline demographic characteristics, with endometrial cancer more prevalent in the consistent-IO group. RDI was significantly less reduced in the consistent-IO chemotherapy group (p = 0.005). During taxane-based regimens, RDI was better maintained in the consistent-IO group (0.93 vs. 0.87, p = 0.012), though not with platinum-based cycles. Linear regression model found a correlation between preserved RDI and consistent attendance at weekly IO treatments, and lower rates of chemotherapy-induced peripheral neuropathy and pain.
Conclusion
Patient-tailored IO programs for patients with advanced gynecological cancer may help preserve adherence to chemotherapy at 6 weeks, especially with taxane-based regimens. Further research needs to explore whether this correlation is chemotherapy agent–specific.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-022-06865-2</identifier><identifier>PMID: 35094141</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer ; Care and treatment ; Chemotherapy ; Comparative analysis ; Complementary Therapies ; Endometrial cancer ; Female ; Genital Neoplasms, Female - drug therapy ; Gynecological cancer ; Gynecology ; Humans ; Integrative Oncology ; Medical care ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Nursing ; Nursing Research ; Oncology ; Original Article ; Pain Medicine ; Patient compliance ; Patient-centered care ; Patients ; Prospective Studies ; Quality management ; Quality of Life ; Rehabilitation Medicine</subject><ispartof>Supportive care in cancer, 2022-05, Vol.30 (5), p.4345-4354</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-618515b5dd2ff94ab1f41189ad8754f824022fdf5cc47d69e7a05fede05cf19f3</citedby><cites>FETCH-LOGICAL-c486t-618515b5dd2ff94ab1f41189ad8754f824022fdf5cc47d69e7a05fede05cf19f3</cites><orcidid>0000-0002-4058-3672</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-022-06865-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-022-06865-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35094141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ben-Arye, Eran</creatorcontrib><creatorcontrib>Nijk, Naama</creatorcontrib><creatorcontrib>Lavie, Ofer</creatorcontrib><creatorcontrib>Gressel, Orit</creatorcontrib><creatorcontrib>MD, Elad Schiff</creatorcontrib><creatorcontrib>Samuels, Noah</creatorcontrib><title>Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer?</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Objective
Integrative oncology (IO) has been shown to improve quality-of-life (QoL) and increase adherence to planned chemotherapy regimens. This study examined the impact of a patient-tailored IO program on adherence to chemotherapy among patients with advanced gynecological cancer.
Methods
This prospective non-randomized, pragmatic, preference study examined patients with stage III/IV gynecological cancers undergoing 6 weeks of weekly IO treatments. Adherence to the planned chemotherapy regimen was assessed using the relative dose intensity (RDI) calculation. Patients consistently attending IO treatments (consistent-IO group) were compared to those who were not (non-consistent IO group).
Results
RDI was calculated for 73 patients in the consistent-IO group (99 chemotherapy cycles) and 61 in the non-consistent-IO group (96 cycles with IO care, 126 cycles without). Both groups had similar baseline demographic characteristics, with endometrial cancer more prevalent in the consistent-IO group. RDI was significantly less reduced in the consistent-IO chemotherapy group (p = 0.005). During taxane-based regimens, RDI was better maintained in the consistent-IO group (0.93 vs. 0.87, p = 0.012), though not with platinum-based cycles. Linear regression model found a correlation between preserved RDI and consistent attendance at weekly IO treatments, and lower rates of chemotherapy-induced peripheral neuropathy and pain.
Conclusion
Patient-tailored IO programs for patients with advanced gynecological cancer may help preserve adherence to chemotherapy at 6 weeks, especially with taxane-based regimens. Further research needs to explore whether this correlation is chemotherapy agent–specific.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Comparative analysis</subject><subject>Complementary Therapies</subject><subject>Endometrial cancer</subject><subject>Female</subject><subject>Genital Neoplasms, Female - drug therapy</subject><subject>Gynecological cancer</subject><subject>Gynecology</subject><subject>Humans</subject><subject>Integrative Oncology</subject><subject>Medical care</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Patient compliance</subject><subject>Patient-centered care</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Quality management</subject><subject>Quality of Life</subject><subject>Rehabilitation Medicine</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUuLFDEUhYMoTjv6B1xIgRs3NebmVZWVDI0vGHCjKxchndzU1FCVtEn1QP97U9OjgyKSReCc71zu5RDyEugFUNq9LZRKRlvKWEtVr2TLHpENCM7bjnP9mGyoFtAKLuUZeVbKDaXQdZI9JWdcrpaADfm-tbEZ44JDtst4i02KLk1pOFbRZbQFG-uvMWN02Cypcdc4p6UKdr8i1by11fLNcIx4lxxd41Ypv3tOngQ7FXxx_5-Tbx_ef91-aq--fPy8vbxqnejV0iroJcid9J6FoIXdQRAAvba-76QIPRP1wuCDdE50XmnsLJUBPVLpAujAz8mb09x9Tj8OWBYzj8XhNNmI6VAMU0yA1qyTFX39F3qTDjnW7SolGIBUXDxQg53QjDGkJVu3DjWXSvcAFNRKXfyDqs_jPLoUMYxV_yPATgGXUykZg9nncbb5aICatVFzatTUe81do4bV0Kv7jQ-7Gf3vyK8KK8BPQKlWHDA_nPSfsT8BVbqqQg</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Ben-Arye, Eran</creator><creator>Nijk, Naama</creator><creator>Lavie, Ofer</creator><creator>Gressel, Orit</creator><creator>MD, Elad Schiff</creator><creator>Samuels, Noah</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4058-3672</orcidid></search><sort><creationdate>20220501</creationdate><title>Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer?</title><author>Ben-Arye, Eran ; Nijk, Naama ; Lavie, Ofer ; Gressel, Orit ; MD, Elad Schiff ; Samuels, Noah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-618515b5dd2ff94ab1f41189ad8754f824022fdf5cc47d69e7a05fede05cf19f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Comparative analysis</topic><topic>Complementary Therapies</topic><topic>Endometrial cancer</topic><topic>Female</topic><topic>Genital Neoplasms, Female - drug therapy</topic><topic>Gynecological cancer</topic><topic>Gynecology</topic><topic>Humans</topic><topic>Integrative Oncology</topic><topic>Medical care</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Patient compliance</topic><topic>Patient-centered care</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Quality management</topic><topic>Quality of Life</topic><topic>Rehabilitation Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ben-Arye, Eran</creatorcontrib><creatorcontrib>Nijk, Naama</creatorcontrib><creatorcontrib>Lavie, Ofer</creatorcontrib><creatorcontrib>Gressel, Orit</creatorcontrib><creatorcontrib>MD, Elad Schiff</creatorcontrib><creatorcontrib>Samuels, Noah</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ben-Arye, Eran</au><au>Nijk, Naama</au><au>Lavie, Ofer</au><au>Gressel, Orit</au><au>MD, Elad Schiff</au><au>Samuels, Noah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer?</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>30</volume><issue>5</issue><spage>4345</spage><epage>4354</epage><pages>4345-4354</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Objective
Integrative oncology (IO) has been shown to improve quality-of-life (QoL) and increase adherence to planned chemotherapy regimens. This study examined the impact of a patient-tailored IO program on adherence to chemotherapy among patients with advanced gynecological cancer.
Methods
This prospective non-randomized, pragmatic, preference study examined patients with stage III/IV gynecological cancers undergoing 6 weeks of weekly IO treatments. Adherence to the planned chemotherapy regimen was assessed using the relative dose intensity (RDI) calculation. Patients consistently attending IO treatments (consistent-IO group) were compared to those who were not (non-consistent IO group).
Results
RDI was calculated for 73 patients in the consistent-IO group (99 chemotherapy cycles) and 61 in the non-consistent-IO group (96 cycles with IO care, 126 cycles without). Both groups had similar baseline demographic characteristics, with endometrial cancer more prevalent in the consistent-IO group. RDI was significantly less reduced in the consistent-IO chemotherapy group (p = 0.005). During taxane-based regimens, RDI was better maintained in the consistent-IO group (0.93 vs. 0.87, p = 0.012), though not with platinum-based cycles. Linear regression model found a correlation between preserved RDI and consistent attendance at weekly IO treatments, and lower rates of chemotherapy-induced peripheral neuropathy and pain.
Conclusion
Patient-tailored IO programs for patients with advanced gynecological cancer may help preserve adherence to chemotherapy at 6 weeks, especially with taxane-based regimens. Further research needs to explore whether this correlation is chemotherapy agent–specific.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35094141</pmid><doi>10.1007/s00520-022-06865-2</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4058-3672</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2022-05, Vol.30 (5), p.4345-4354 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2624199275 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Care and treatment Chemotherapy Comparative analysis Complementary Therapies Endometrial cancer Female Genital Neoplasms, Female - drug therapy Gynecological cancer Gynecology Humans Integrative Oncology Medical care Medical research Medicine Medicine & Public Health Medicine, Experimental Nursing Nursing Research Oncology Original Article Pain Medicine Patient compliance Patient-centered care Patients Prospective Studies Quality management Quality of Life Rehabilitation Medicine |
| title | Can integrative oncology increase adherence to chemotherapy in advanced gynecologic cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A03%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20integrative%20oncology%20increase%20adherence%20to%20chemotherapy%20in%20advanced%20gynecologic%20cancer?&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Ben-Arye,%20Eran&rft.date=2022-05-01&rft.volume=30&rft.issue=5&rft.spage=4345&rft.epage=4354&rft.pages=4345-4354&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-022-06865-2&rft_dat=%3Cgale_proqu%3EA698110164%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642115634&rft_id=info:pmid/35094141&rft_galeid=A698110164&rfr_iscdi=true |